The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Mostrar otras versiones (1)

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side effects rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndeupen, Sonia, Qin, Zhen, Jacobsen, Sonya, Bouteau, Aurélie, Estanbouli, Henri, Igyártó, Botond Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604799/
https://www.ncbi.nlm.nih.gov/pubmed/34841223
http://dx.doi.org/10.1016/j.isci.2021.103479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604799/
https://www.ncbi.nlm.nih.gov/pubmed/34841223
http://dx.doi.org/10.1016/j.isci.2021.103479

Ejemplares similares